A Novel Hydrogen Sulfide Prodrug, SG1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients

Recent studies demonstrate robust molecular cross talk and signaling between hydrogen sulfide (H(2)S) and nitric oxide (NO). Heart failure (HF) patients are deficient in both H(2)S and NO, two molecules that are critical for cardiovascular homeostasis. A phase I clinical trial of a novel H(2)S prodr...

Descripción completa

Detalles Bibliográficos
Autores principales: Polhemus, David J., Li, Zhen, Pattillo, Christopher B., Gojon, Gabriel, Giordano, Tony, Krum, Henry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Expedited
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034803/
https://www.ncbi.nlm.nih.gov/pubmed/25930144
http://dx.doi.org/10.1111/1755-5922.12128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034803/
https://www.ncbi.nlm.nih.gov/pubmed/25930144
http://dx.doi.org/10.1111/1755-5922.12128

Ejemplares similares